These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 32179964)

  • 21. Real-world clinical experience of biological disease modifying anti-rheumatic drugs in Malaysia rheumatoid arthritis patients.
    Tan BE; Lim AL; Kan SL; Lim CH; Tsang EEL; Ch'ng SS; Mohd Noor N; Mohd Jamid N; Teh CL; Joshua Thundyil R; Loh YL; Chong HC; Ong SG; Mohamed Ismail A; Lee YYL; Gun SC
    Rheumatol Int; 2017 Oct; 37(10):1719-1725. PubMed ID: 28695274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
    Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
    Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of biologics and targeted synthetic disease-modifying anti-rheumatic drugs on fatigue in rheumatoid arthritis.
    Choy EH
    Rheumatology (Oxford); 2019 Nov; 58(Suppl 5):v51-v55. PubMed ID: 31682274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tocilizumab in the treatment of adult rheumatoid arthritis.
    Sanmartí R; Ruiz-Esquide V; Bastida C; Soy D
    Immunotherapy; 2018 Mar; 10(6):447-464. PubMed ID: 29495891
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Strategies toward rheumatoid arthritis therapy; the old and the new.
    Abbasi M; Mousavi MJ; Jamalzehi S; Alimohammadi R; Bezvan MH; Mohammadi H; Aslani S
    J Cell Physiol; 2019 Jul; 234(7):10018-10031. PubMed ID: 30536757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low rates of remission with methotrexate monotherapy in rheumatoid arthritis: review of randomised controlled trials could point towards a paradigm shift.
    Chatzidionysiou K; Sfikakis PP
    RMD Open; 2019; 5(2):e000993. PubMed ID: 31413870
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis.
    Donahue KE; Gartlehner G; Jonas DE; Lux LJ; Thieda P; Jonas BL; Hansen RA; Morgan LC; Lohr KN
    Ann Intern Med; 2008 Jan; 148(2):124-34. PubMed ID: 18025440
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
    Ciubotariu E; Gabay C; Finckh A;
    J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis.
    Naerr GW; Rein P; Saely CH; Drexel H
    Vascul Pharmacol; 2016 Jun; 81():22-30. PubMed ID: 26903239
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Baricitinib for the treatment of rheumatoid arthritis.
    Kubo S; Nakayamada S; Tanaka Y
    Expert Rev Clin Immunol; 2016 Sep; 12(9):911-9. PubMed ID: 27427830
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update on the use of conventional disease-modifying antirheumatic drugs in the management of rheumatoid arthritis.
    Feely MG; O'Dell JR
    Curr Opin Rheumatol; 2010 May; 22(3):316-20. PubMed ID: 20190639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stopping tumour necrosis factor-targeted biological DMARDs in rheumatoid arthritis.
    Tanaka Y
    Rheumatology (Oxford); 2016 Dec; 55(suppl 2):ii15-ii22. PubMed ID: 27856656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ultrasonographic Efficacy of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drug Therapy in Rheumatoid Arthritis From a Multicenter Rheumatoid Arthritis Ultrasound Prospective Cohort in Japan.
    Nishino A; Kawashiri SY; Koga T; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Ueki Y; Yoshitama T; Eiraku N; Matsuoka N; Okada A; Fujikawa K; Hamada H; Tsuru T; Nagano S; Arinobu Y; Hidaka T; Kawakami A
    Arthritis Care Res (Hoboken); 2018 Dec; 70(12):1719-1726. PubMed ID: 29481732
    [TBL] [Abstract][Full Text] [Related]  

  • 34. No predictive effect of body mass index on clinical response in patients with rheumatoid arthritis after 24 weeks of biological disease-modifying antirheumatic drugs: a single-center study.
    Kim SK; Choe JY; Park SH; Lee H
    Clin Rheumatol; 2016 May; 35(5):1129-36. PubMed ID: 26932795
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis.
    Henaux S; Ruyssen-Witrand A; Cantagrel A; Barnetche T; Fautrel B; Filippi N; Lukas C; Raffeiner B; Rossini M; Degboé Y; Constantin A
    Ann Rheum Dis; 2018 Apr; 77(4):515-522. PubMed ID: 29187350
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rheumatoid arthritis management of early disease.
    Nam JL
    Curr Opin Rheumatol; 2016 May; 28(3):267-74. PubMed ID: 26978129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
    Kim G; Barner JC; Rascati K; Richards K
    Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of rheumatoid arthritis by molecular-targeted agents: efficacy and limitations.
    Koike T
    J Orthop Sci; 2015 Nov; 20(6):951-7. PubMed ID: 26404390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Drug therapy of rheumatoid arthritis: where do biologics and novel synthetic disease-modifying antirheumatic drugs stand today?].
    Kaudewitz D; Lorenz HM
    Inn Med (Heidelb); 2023 Oct; 64(10):1005-1012. PubMed ID: 37493758
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination conventional DMARDs compared to biologicals: what is the evidence?
    Sethi MK; O'Dell JR
    Curr Opin Rheumatol; 2015 Mar; 27(2):183-8. PubMed ID: 25603037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.